BridgeBio Pharma PE Ratio 2018-2024 | BBIO

Current and historical p/e ratio for BridgeBio Pharma (BBIO) from 2018 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. BridgeBio Pharma PE ratio as of November 20, 2024 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

BridgeBio Pharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-11-19 22.54 0.00
2024-09-30 25.46 $-2.41 0.00
2024-06-30 25.33 $-2.63 0.00
2024-03-31 30.92 $-3.22 0.00
2023-12-31 40.37 $-3.94 0.00
2023-09-30 26.37 $-3.90 0.00
2023-06-30 17.20 $-3.75 0.00
2023-03-31 16.58 $-2.84 0.00
2022-12-31 7.62 $-3.27 0.00
2022-09-30 9.94 $-3.36 0.00
2022-06-30 9.08 $-3.49 0.00
2022-03-31 10.15 $-4.08 0.00
2021-12-31 16.68 $-3.91 0.00
2021-09-30 46.87 $-3.91 0.00
2021-06-30 60.96 $-3.83 0.00
2021-03-31 61.60 $-4.20 0.00
2020-12-31 71.11 $-3.80 0.00
2020-09-30 37.52 $-3.41 0.00
2020-06-30 32.61 $-2.43 0.00
2020-03-31 29.00 $-1.91 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00